Immunomedics' executive chairman, Behzad Aghazadeh, is on tap for $2.35 billion from the company's $21 billion sale to Gilead Sciences. (Getty Images) () Thanks to Gilead Sciences, which is splashing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results